Practice Expertise

  • Health & Life Sciences
  • Health Information Technology, Privacy & ...
  • Data Privacy & Security
  •  

Areas of Practice

  • Data Privacy & Security
  • Health & Life Sciences
  • Health Information Technology, Privacy & ...
  • Data Privacy & Security
  • Health & Life Sciences
  • Health Information Technology, Privacy and ...
  • Pharmacy, Drug and Device
  • Telehealth
  • View More

Profile

Ensuring regulatory compliance for pharmaceutical industry clients

Benjamin Lockwood counsels clients on a wide variety of legal matters for health care clients, including many pharmaceutical industry clients such as:

  • Manufacturers
  • Distributors
  • Pharmacies
  • Other related entities

Benjamin provides strategic counsel in three primary areas: ensuring compliance with HIPAA and other data privacy and security regulations; advising clients on various Food and Drug Administration (FDA) regulations, with a specific focus on drug and device advertising compliance; and counseling health care clients on nationwide licensing and permitting requirements.

Bar Admissions

  • Wisconsin

Education

  • Marquette University (B.A., cum laude, 2016)
  • University of Wisconsin Law School (J.D., 2019)
    • L. Edward Bryant, Jr. National Health Law Transactional Moot Court Competition (competitor)
    • Duberstein (Bankruptcy Law) Moot Court Competition (coach)

Areas of Practice

  • Data Privacy & Security
  • Health & Life Sciences
  • Health Information Technology, Privacy & Security
  • Data Privacy & Security
  • Health & Life Sciences
  • Health Information Technology, Privacy and Security
  • Pharmacy, Drug and Device
  • Telehealth

Professional Career



Articles

  • 503B Loses Federal Preemption Argument, Appeals to Ninth Circuit
  • Drug Supply Chain Security Act Compliance Extended But Trading Partners Should Still Prepare Now
  • FDA Announces Draft Guidance on Outsourcing Facility Sales
  • FDA Announces Guidance for DSCSA Process to Request a Waiver, Exception, or Exemption
  • FDA Releases Draft Interim Guidance on Bulk Drug Substances in Compounding Under Sections 503A and 503B of FDCA
  • High Court Rules “State of Mind” Relevant in Prosecuting Prescribers under the Controlled Substance Act
  • Interesting 340B Takeaways from 2020 OPPS Proposed Rule
  • Joint Commission Issues Sentinel Event Alert on Cybersecurity in Health Care
  • June is LGBTQ Pride Month, Come Celebrate with Us!
  • More Guidance Released from FDA for Drug Supply Chain Security Act Compliance
  • Oklahoma Board of Pharmacy Proposes Temperature Control Rule for Shipping Drugs
  • Recent Updates: Data Privacy & Security for Health Care Entities Summer 2022
  • With CCPA in Effect, What Do Health and Life Sciences Entities Need to Know? And How Does the New Amendment Affect You?
  • With CCPA in Effect, What Does Your Business Need to Know to Comply?

Meet our Firms and Professionals

WSG’s member firms include legal, investment banking and accounting experts across industries and on a global scale. We invite you to meet our member firms and professionals.